

Abstract

5 Pharmaceutical compositions containing as active
 compound a substance which inhibits the activity of TGF β
 on tumour cells of epithelial origin, for the treatment
 of epithelial, invasive tumour diseases which are
 characterised by a reversible transition of the cells
 10 from an epithelial, non-invasive state into a
 fibroblastoid, invasive state. The pharmaceutical
 composition contains a TGF β inhibitor, preferably
 combined with an Ras inhibitor. Process for screening
 substances for the treatment of epithelial, invasive
 15 tumour diseases.